ALGN Stock Analysis: Align Technology | NASDAQ
Medical Instruments & Supplies | NASDAQ, USA | Market Cap: 10.585m USD | 12M Return: 11.5% | US0162551016 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 133M
EPS Trend: 94.2%
Qual. Beats: 0
Rev. Trend: 93.7%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Align Technology, Inc. (NASDAQ: ALGN) is a global medical device company that designs, manufactures, and markets the Invisalign system of clear aligners, Vivera retainers, and iTero intraoral scanners and related services. The company operates through two main segments: Clear Aligner and Imaging Systems and CAD/CAM Services. The Clear Aligner segment offers a wide range of Invisalign products targeting adults, teens, and younger patients (ages 6-10) with mixed dentition, including various treatment tiers (Express, Lite, Moderate, Go), retention products, training tools, the Invisalign Professional Whitening system, and the Invisalign Palatal Expander, a 3D printed orthodontic device. The Imaging Systems and CAD/CAM Services segment provides the iTero intraoral scanner, exocad design software, orthodontic and restorative software, and various digital tools such as the Invisalign Outcome Simulator, Progress Assessment tool, Oral Health Suite, and iTero TimeLapse technology, supported by subscription software, disposables, scanner rentals, and pay-per-scan services.
Founded in 1997 and headquartered in Tempe, Arizona, Align Technology is classified within the Health Care sector, specifically the Health Care Supplies sub-industry, and has a mid-cap market capitalization of approximately $9.94 billion. The company operates in the United States, Switzerland, and internationally, and was IPOd on January 26, 2001. Align Technologys business model is heavily focused on orthodontics and digital dentistry, leveraging proprietary 3D printing and scanning technologies to serve dental professionals, orthodontists, and patients globally. As a key player in the clear aligner market, Align Technology competes in a growing segment of the dental industry, which is increasingly shifting toward digital workflows and minimally invasive cosmetic dental solutions.
- Invisalign teen and Phase I expansion drives adolescent case volume
- iTero scanner adoption and subscription software recurring revenue
- Consumer discretionary dental spending weakness pressures clear aligner ASPs
- Chinese growth and APAC expansion offset mature US market saturation
- Class action litigation and regulatory scrutiny over clear aligner marketing practices
- Capital allocation through share buybacks and margin discipline from cost optimization
| Net Income: 413.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 0.87 > 1.0 |
| NWC/Revenue: 18.23% < 20% (prev 11.41%; Δ 6.81% < -1%) |
| CFO/TA 0.12 > 3% & CFO 755.7m > Net Income 413.6m |
| Net Debt (-981.7m) to EBITDA (786.3m): -1.25 < 3 |
| Current Ratio: 1.40 > 1.5 & < 3 |
| Outstanding Shares: last quarter (71.6m) vs 12m ago -1.33% < -2% |
| Gross Margin: 66.48% > 18% (prev 69.79%; Δ -3.31% > 0.5%) |
| Asset Turnover: 65.52% > 50% (prev 63.75%; Δ 1.76% > 0%) |
| Interest Coverage Ratio: 10.53 > 6 (EBIT TTM 628.6m / Interest Expense TTM 59.7m) |
| A: 0.12 (Total Current Assets 2.66b - Total Current Liabilities 1.91b) / Total Assets 6.42b |
| B: 0.40 (Retained Earnings 2.60b / Total Assets 6.42b) |
| C: 0.10 (EBIT TTM 628.6m / Avg Total Assets 6.32b) |
| D: 1.94 (Book Value of Equity 4.23b / Total Liabilities 2.19b) |
| Altman-Z'' = 4.79 = AA |
| DSRI: 0.95 (Receivables 1.15b/1.15b, Revenue 4.14b/3.96b) |
| GMI: 1.05 (GM 69.79% / 66.48%) |
| AQI: 1.07 (AQ_t 0.41 / AQ_t-1 0.38) |
| SGI: 1.04 (Revenue 4.14b / 3.96b) |
| TATA: -0.05 (NI 413.6m - CFO 755.7m) / TA 6.42b) |
| Beneish M = -2.95 (Cap -4..+1) = A |
As of October 21, 2026, the stock is trading at USD 150.50 with a total of 912,603 shares traded. Over the past week, the price has changed by +4.85%, over one month by +2.46%, over three months by -14.03% and over the past year by +11.54%.
Current recommended Stop Loss: 144.90 (which is 3.7% or 1.3 ATR below the current price).
Align Technology has received a consensus analysts rating of 3.75. Therefore, it is recommended to hold ALGN.
- StrongBuy: 5
- Buy: 3
- Hold: 7
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 193.8 | 28.8% |
P/E Trailing = 25.6014
P/E Forward = 11.6686
P/S = 2.557
P/B = 2.487
P/EG = 0.6239
Revenue TTM = 4.14b USD
EBIT TTM = 628.6m USD
EBITDA TTM = 786.3m USD
Long Term Debt = 86.6m USD (estimated: total debt 120.8m - short term 34.2m)
Short Term Debt = 34.2m USD (from shortTermDebt, last quarter)
Debt = 120.8m USD (from shortLongTermDebtTotal, last quarter) (leases 120.8m already included)
Net Debt = -981.7m USD (calculated: Debt 120.8m - CCE 1.10b)
Enterprise Value = 9.60b USD (10.6b + Debt 120.8m - CCE 1.10b)
Interest Coverage Ratio = 10.53 (Ebit TTM 628.6m / Interest Expense TTM 59.7m)
EV/FCF = 12.71x (Enterprise Value 9.60b / FCF TTM 755.7m)
FCF Yield = 7.87% (FCF TTM 755.7m / Enterprise Value 9.60b)
FCF Margin = 18.26% (FCF TTM 755.7m / Revenue TTM 4.14b)
Net Margin = 9.99% (Net Income TTM 413.6m / Revenue TTM 4.14b)
Gross Margin = 66.48% ((Revenue TTM 4.14b - Cost of Revenue TTM 1.39b) / Revenue TTM)
Gross Margin QoQ = 65.14% (prev 70.82%)
Tobins Q-Ratio = 1.50 (Enterprise Value 9.60b / Total Assets 6.42b)
Interest Expense / Debt = 49.41% (Interest Expense 59.7m / Debt 120.8m)
Taxrate = 27.30% (155.3m / 568.9m)
NOPAT = 457.0m (EBIT 628.6m * (1 - 27.30%))
Current Ratio = 1.40 (Total Current Assets 2.66b / Total Current Liabilities 1.91b)
Debt / Equity = 0.03 (Debt 120.8m / totalStockholderEquity, last quarter 4.23b)
Debt / EBITDA = -1.25 (Net Debt -981.7m / EBITDA 786.3m)
Debt / FCF = -1.30 (Net Debt -981.7m / FCF TTM 755.7m)
Total Stockholder Equity = 4.10b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.55% (Net Income 413.6m / Total Assets 6.42b)
RoE = 10.09% (Net Income TTM 413.6m / Total Stockholder Equity 4.10b)
RoCE = 15.03% (EBIT 628.6m / Capital Employed (Equity 4.10b + L.T.Debt 86.6m))
RoIC = 10.54% (NOPAT 457.0m / Invested Capital 4.34b)
WACC = 9.16% (E(10.6b)/V(10.7b) * Re(8.85%) + D(120.8m)/V(10.7b) * Rd(49.41%) * (1-Tc(0.27)))
Discount Rate = 8.85% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -97.73 | Cagr: -2.21%
[DCF] Terminal Value 74.15% ; FCFF base≈724.7m ; Y1≈796.3m ; Y5≈1.01b
[DCF] Fair Price = 204.4 (EV 13.5b - Net Debt -981.7m = Equity 14.5b / Shares 71.0m; r=9.16% [WACC]; 5y FCF grow 11.41% → 2.50% )
EPS Correlation: 94.17 | EPS CAGR: 10.01% | SUE: -0.21 | # QB: 0
Revenue Correlation: 93.70 | Revenue CAGR: 2.42% | SUE: 0.03 | # QB: 0
EPS current Quarter (2026-09-30): EPS=2.78 | Chg30d=-0.50% | Revisions=-25% | Analysts=14
EPS current Year (2026-12-31): EPS=11.26 | Chg30d=-0.32% | Revisions=-40% | GrowthEPS=+7.1% | GrowthRev=+2.9%
EPS next Year (2027-12-31): EPS=12.43 | Chg30d=-0.98% | Revisions=-40% | GrowthEPS=+10.4% | GrowthRev=+3.6%
[Analyst] Revisions Ratio: -62% (up=0, down=5)